Merck Achieves Record High Stock Value Following Strong Q4 Sales

Surpassing expectations, Merck's Q4 earnings reveal significant growth in cancer drug and vaccine sales, setting a new record for the company's stock price.

• Merck & Co. reported a surprise adjusted profit for Q4, driven by a 21% increase in Keytruda cancer drug sales and a 27% rise in Gardasil HPV vaccine sales.
• Despite a fourth-quarter loss of $1.23 billion due to charges from a collaboration, Merck's revenue rose 6% to $14.63 billion.
• The company's shares reached an all-time high, closing at $126.42, after early trading saw a peak of $123.92.
• Merck anticipates full-year earnings per share (EPS) of $8.44 to $8.59, exceeding analyst expectations.
• Investments in research and development totaled approximately $30 billion, aiming to propel the next generation of medical innovations.

3 Articles

Investopedia Benzinga CNBC